Organisation paid for research Program year 2025 Source: CMS Open Payments

Baylor Research Institute

Neither a doctor nor a teaching hospital

Research payments

$73,731,349

10,833 payments

Through program year 2025, Baylor Research Institute is reported as receiving $73,731,349 in research payments, across 10,833 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $8,792,723 1,438
2024 Research $10,071,292 1,418
2023 Research $7,019,643 1,376
2022 Research $7,700,132 1,437
2021 Research $13,093,644 1,618
2020 Research $17,072,054 2,247
2019 Research $9,981,861 1,299

Breakdown

Who paid Research payments · program years 2019–2025
  1. Edwards Lifesciences Corporation $9,670,076 991 payments
  2. Medtronic, Inc. $6,225,013 772 payments
  3. Boston Scientific Corporation $5,979,406 891 payments
  4. Eli Lilly and Company $5,196,806 67 payments
  5. Gilead Sciences, Inc. $5,108,645 179 payments
  6. Abbott Laboratories $5,058,698 1,065 payments
  7. Medtronic Vascular, Inc. $3,851,386 382 payments
  8. Stemline Therapeutics Inc. $3,493,525 87 payments
  9. Janssen Research & Development, LLC $3,476,652 297 payments
  10. Regeneron Pharmaceuticals, Inc. $2,481,984 147 payments
Studies the money was for Research payments · program years 2019–2025
  1. Spyral Affirm $3,114,409 87 payments
  2. Acurate Ide $2,978,884 240 payments
  3. Phase 2 Randomized Double blind Placebo controlled Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed COVID19 Severe Disease $2,108,161 26 payments
  4. Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme $2,097,137 21 payments
  5. Spyral Htn-On Med $2,020,687 103 payments
  6. A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Hospitalized Patients With COVID-19 $1,667,934 53 payments
  7. A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Mono and Combination Therapy With Monoclonal Antibodies in Participants With Mild to Moderate Covid-19 Illness (Blaze-4) $1,436,006 3 payments
  8. Spyral Htn-Off Med $1,423,959 78 payments
  9. Evoque Tr 2019-06 $1,413,257 93 payments
  10. Stml-401-0114 $1,335,635 7 payments
What the money was spent on Research payments · program years 2019–2025
  1. Patient care $89,051 34 payments
  2. Other $30,349 20 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record